Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

AOD9604 (Fragment 176-191): what it is studied alongside

AOD9604 (hGH fragment 176-191) is a research peptide studied alongside GHRH analogues, ghrelin-receptor secretagogues and IGF-1 analogues within the GH-IGF-1 axis literature.

peptides-pro Editorial

AOD9604, also written AOD-9604 and hGH fragment 176-191, is the C-terminal fragment of human growth hormone corresponding to residues 176 through 191, and it is classed in the research literature as a growth hormone fragment rather than a full-length somatotropin or a secretagogue. The evidence block used for this page does not supply a sequence string, a molecular formula or a molecular weight for the fragment, so none are stated here; what it does supply is the naming convention, the fragment designation, and the abbreviation AOD-9604, expanded in one source as Anti-Obesity Drug 96 [2][3]. The same source places peptides generally as short amino-acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and places AOD-9604 within a set of compounds marketed directly to patients outside the approval pathway [2][3].

The work that frames this compound centres on the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis, the endocrine signalling route through which growth hormone release and downstream IGF-1 activity are coupled [1].

Research Studies

AOD9604 and the GH-IGF-1 axis compound landscape

A review of performance-enhancing peptides that modulate the GH-IGF-1 axis lists AOD9604 (hGH 176-191) among the agents most commonly encountered both in clinical practice and in online self-administration protocols [1]. The same review groups the field into GHRH analogues, growth hormone secretagogues, the growth hormone fragment, and IGF-1 analogues, and notes that these products are marketed as research compounds while remaining unregulated [1]. That framing matters for how the fragment is studied: it is positioned in the literature as one node in a family of GH-axis agents rather than as a standalone category, and comparisons in that literature are typically drawn across the family.

Class in the GH-IGF-1 axis reviewExamples named in the source
GHRH analoguessermorelin, tesamorelin, CJC-1295 with DAC, CJC-1295 without DAC
Growth hormone secretagoguesGHRP-2, GHRP-6, hexarelin, ipamorelin
Growth hormone fragmentAOD9604 (hGH 176-191)
IGF-1 analogueIGF-1 analogue (as grouped in the source)

Because the review presents these as co-occurring categories rather than as a ranked list, the table above should be read as a map of the literature, not as a statement about relative activity or interchangeability [1].

AOD9604 and GHRH analogues

GHRH analogues act upstream at the level of growth hormone release, and the review places sermorelin, tesamorelin and the two CJC-1295 variants in that group alongside the growth hormone fragment [1]. The practical consequence for research design is that a study examining the fragment in the presence of a GHRH analogue is examining two different points on the same axis: one acting on secretagogue-driven release, the other being a fragment of the hormone itself. The evidence block does not report a study in which AOD9604 and a named GHRH analogue were co-administered, so no such finding is claimed here; what the source supports is the classification of both within the same axis-modulating set [1].

AOD9604 and growth hormone secretagogues

Growth hormone secretagogues named in the review include GHRP-2, GHRP-6, hexarelin and ipamorelin [1]. These are grouped separately from the growth hormone fragment, which means the literature treats them as a distinct mechanistic class even though all are discussed under the same GH-IGF-1 heading. For a reader trying to understand what AOD9604 is studied alongside, the secretagogues are the most frequently co-listed category in the review's framing, and the distinction between a secretagogue and a hormone fragment is the distinction the source draws most clearly [1].

AOD9604 and IGF-1 analogues

The review also lists an IGF-1 analogue as part of the same set of agents encountered in self-administration protocols [1]. IGF-1 sits downstream of growth hormone in the axis, so an IGF-1 analogue and a growth hormone fragment occupy different positions along the same signalling route. The evidence block does not describe a combined study of the two, and none is asserted here; the supportable statement is that both appear in the same review as axis-modulating agents marketed as research compounds [1].

AOD9604 and musculoskeletal injury research

A separate review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance names AOD-9604 (Anti-Obesity Drug 96) among the peptides it covers, and describes the broader context as a rapidly expanding use of peptides in sports medicine driven by demand for accelerated injury recovery and performance enhancement [2][3]. The same source characterises a parallel gray market of unapproved compounds operating largely outside regulatory oversight [2][3]. A related reference-only paper on therapeutic peptides in orthopaedics reports that peptides act on pathways including PI3K/Akt, mTOR, MAPK, TGF-beta and AMPK, and that this pathway engagement underlies their proposed influence on tissue regeneration [6]. That paper is a general statement about therapeutic peptides in orthopaedics and is not specific to AOD9604; it is included here because it describes the mechanistic vocabulary in which musculoskeletal peptide research is conducted [6].

AOD9604 and analytical detection workflows

A reference-only study reports a rapid, harmonised analytical workflow for detecting peptidic and non-peptidic doping agents in dried and liquid blood matrices, covering 54 prohibited substances, and notes that earlier dried-blood-spot methods for small peptides required multiple preparation steps and were labour-intensive and costly [4]. This work is not an efficacy study and says nothing about what the fragment does; it is relevant only in that it establishes that small peptides are a defined analytical target class in blood matrices [4]. No detection result specific to AOD9604 is reported in the evidence block, and none is claimed.

AOD9604 and regulatory status in the peptide literature

Both versions of the musculoskeletal peptide review state that while numerous peptide drugs have undergone a rigorous approval process evaluating safety and efficacy, a parallel gray market of unapproved compounds has emerged outside regulatory oversight, and both name AOD-9604 within that discussion [2][3]. The GH-IGF-1 review makes a comparable observation, describing peptides marketed as research compounds that are intended to modulate the axis and that appear in online self-administration protocols [1]. Taken together, the sources place the fragment on the unapproved side of the regulatory line while noting its frequent appearance in the same discussions as approved agents [1][2][3].

AOD9604 and the limits of the current evidence

The evidence block assembled for this page does not contain an animal study, a human trial, a dose-response experiment or a receptor-binding assay specific to AOD9604. What it contains is classification and context: the fragment's place in the GH-IGF-1 axis literature [1], its inclusion in a review of approved and unapproved peptides for musculoskeletal and athletic applications [2][3], a general statement about peptide signalling pathways in orthopaedics [6], and an analytical workflow paper covering small peptides as a detection class [4]. Any statement about what the fragment does in a given tissue or model would require evidence that is not present here, and is therefore omitted rather than inferred. Where a reader encounters claims about the fragment's activity, those claims are not supported by the sources cited on this page.

If you are reading this for personal health reasons

This material is sold for laboratory research use only, and we do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician rather than relying on research summaries or supplier pages. The sources cited here describe classification and regulatory context, not personal-use outcomes.

Sources

WhatsApp